Evidence that phosphorylation by the mitotic kinase Cdk1 promotes ICER monoubiquitination and nuclear delocalization

Elisabeth Mémin1, Megan Genzale, Marni Crow

  • 1Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, NJ 07103, USA.

Insights

Prostate cancer cells lack the Inducible cAMP Early Repressor (ICER) protein in their nuclei. This study reveals that monoubiquitination of ICER by cdk1 causes its cytosolic localization, explaining its abnormal expression in tumors.

Area of Science:

  • Molecular biology
  • Cellular biology
  • Cancer research

Background:

  • The transcriptional repressor Inducible cAMP Early Repressor (ICER) is absent in prostate cancer cell nuclei, unlike normal cells.
  • The underlying molecular mechanisms for ICER's altered expression in prostate cancer are not well understood.

Purpose of the Study:

  • To elucidate the molecular mechanisms behind the abnormal subcellular localization of ICER in prostate cancer cells.
  • To investigate the post-translational modifications of ICER and their effect on its cellular distribution.

Main Methods:

  • Western blotting to detect ICER phosphorylation and ubiquitination.
  • Immunoprecipitation assays to identify interacting proteins.
  • Confocal microscopy to visualize ICER localization within cells.
  • Site-directed mutagenesis to identify phosphorylation and ubiquitination sites.

Main Results:

  • ICER is phosphorylated by the mitotic kinase cdk1.
  • Phosphorylation of ICER targets it for monoubiquitination.
  • Monoubiquitinated ICER exhibits cytosolic localization, distinct from unphosphorylated, phosphorylated, or polyubiquitinated forms.
  • These findings suggest a mechanism for ICER's abnormal cytosolic localization in human prostate tumors.

Conclusions:

  • CDK1-mediated phosphorylation and subsequent monoubiquitination of ICER lead to its cytosolic mislocalization.
  • This mechanism provides a potential explanation for the absence of nuclear ICER in prostate cancer cells.
  • Targeting this pathway could offer new therapeutic strategies for prostate cancer.

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...